Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
Standard
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). / Bug, G; Burchert, A; Wagner, E-M; Kröger, N; Berg, T; Güller, S; Metzelder, S K; Wolf, A; Hünecke, S; Bader, P; Schetelig, J; Serve, H; Ottmann, O G.
In: LEUKEMIA, Vol. 31, No. 11, 11.2017, p. 2523-2525.Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
AU - Bug, G
AU - Burchert, A
AU - Wagner, E-M
AU - Kröger, N
AU - Berg, T
AU - Güller, S
AU - Metzelder, S K
AU - Wolf, A
AU - Hünecke, S
AU - Bader, P
AU - Schetelig, J
AU - Serve, H
AU - Ottmann, O G
N1 - Letter
PY - 2017/11
Y1 - 2017/11
KW - Journal Article
U2 - 10.1038/leu.2017.242
DO - 10.1038/leu.2017.242
M3 - Other (editorial matter etc.)
C2 - 28751769
VL - 31
SP - 2523
EP - 2525
JO - LEUKEMIA
JF - LEUKEMIA
SN - 0887-6924
IS - 11
ER -